Drug delivery specialist Gerresheimer boosts 3rd-quarter revenue; MonoSol grabs Canadian patent tied to drug film tech;

> Drug delivery specialist Gerresheimer said that its third-quarter revenue rose 9.9% to €285.1 million. Report

> Montreal-based Theratechnologies ($THER) said that it has found a new growth-hormone releasing factor peptide (GRF) that could be used in treatments for more medical conditions than its existing GRF. Release

> British drug giant AstraZeneca ($AZ) plans to pump $200 million into a new factory in China to produce injectable and oral drugs. Report

> MonoSol Rx has been granted a Canadian patent related to its drug-delivery film products, two of which have recently gained FDA approval. Item

> Depomed, a developer of extended-release drugs, said that its Gralise tablets for once-daily treatment of pain after shingles are now available. Announcement

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.